Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Amazon and Microsoft Veterans Join Forces with the Allen Institute for A.I. to Launch MajorBoost

MajorBoost

Three tech and healthcare veterans collaborating at the Allen Institute for AI (AI2) today launched MajorBoost. The AI-based communication and decision support company is set to significantly improve efficiency in the healthcare system by reimagining how doctor’s offices and insurance companies communicate with each other. “Instead of spending more time on patient conversations and conducting health care follow-ups, medical providers are spending endless hours on the phone navigating the maze of health insurance call centers,” said Lekshmi Venu, co-founder and CEO of MajorBoost. “MajorBoost empowers providers to get their questions answered quickly, resolve insurance issues faster, and ultimately grow their patient service and human connection.” It’s estimated that medical providers lose $35B annually due to antiquated processes and inefficiencies in the insurance system, simply because they’re trying to confirm patient eligibility, claim status, and other administrative tasks. By serving the more than 2M medical billers, front desk staff and call center staff in the healthcare industry, MajorBoost has the potential to change lives and the nature of work. “The pain is real, and the younger generations aren’t going to put up with the current system,” said Ben Hesketh, co-founder and CTO of MajorBoost. “Our AI-enabled phone automation delivers productivity, intelligence and decision support to healthcare teams, getting them off the phone and back to helping patients.” With general availability imminent, MajorBoost is already working with private practices that report seeing immediate results including a boost in same-day issue resolution rates and more patient conversations by using the AI-based tool. Healthcare providers can register for access to MajorBoost at www.majorboost.com. About MajorBoost MajorBoost is founded by technologists who personally live with the challenges of health insurance reimbursement, and were leaders at major tech companies and health plans. Backed by the Allen Institute for AI, MajorBoost builds cutting edge AI to improve the lives of patients, healthcare workers, and call center agents. About the MajorBoost Founders As CEO of MajorBoost, Lekshmi Venu is building on her experiences at both Amazon and the healthcare industry. Prior to co-founding MajorBoost, Lekshmi led a global data science and AI team at Amazon. After earning her MBA at Harvard Business School, Lekshmi held leadership roles at Express Scripts (Cigna) and a mid-size long-term care distributor. Ben Hesketh, CTO of MajorBoost, is a tech innovator and entrepreneur. Ben created first generation products in IoT, AR/VR and NLP and amassed over fifteen patents to date with Microsoft. He began his software career in video game development soon after graduating from Cambridge with dual degrees. MajorBoost is Ben’s third co-founded startup. Andrew Palmer, VP of Engineering, is a technologist and professional weightlifter with a passion for improving the lives of patients and healthcare providers. After graduating with an Engineering degree from University of Dayton, Andrew developed health insurance software and later joined Microsoft as a software developer. Andrew was a developer at Moz and Rover, and most recently founded and led engineering for a social network with over 500K users. About the Allen Institute for AI (AI2) AI2 was founded in 2014 with the singular focus of conducting high-impact research and engineering in the field of artificial intelligence, all for the common good. AI2 is the creation of Paul Allen, Microsoft co-founder, and is led by Dr. Oren Etzioni, a leading researcher in the field of AI. AI2 employs more than 200 top researchers and engineers from across the globe. To date, AI2 has spun out over 10+ companies via its commercialization arm, the AI2 Incubator. Learn more at allenai.org and ai2incubator.com. Contact Details Owen Media Forrest Carman +1 206-859-3118 forrestc@owenmedia.com Company Website https://www.majorboost.com/

July 15, 2021 07:03 PM Eastern Daylight Time

Modulus Therapeutics Secures Funding for Cell Therapy Design Platform, Adds Alana Welm and Raphael Gottardo to Advisory Board

Modulus

Modulus Therapeutics, an artificial-intelligence powered cell therapy design company, announced it completed an oversubscribed $3.5 million Seed round. The round was led by Madrona Venture Group, with participation from KdT Ventures, and the Allen Institute for AI (AI2). Modulus also announced the formation of their Scientific Advisory Board with founding members Alana Welm and Raphael Gottardo. The new funding will be used to expand development of Modulus' Convergent Design™ platform that combines key technology components, including gene editing, machine learning, multi-omics, and high-throughput in vivo screening to bring an intelligent, unbiased approach to immune cell therapy design. “Modulus has an ambitious goal and an innovative platform combining modern machine learning, synthetic biology, and cutting-edge lab automation to treat tumors and eradicate cancer,” said Chris Picardo, Investor at Madrona Venture Group. “Their method unlocks true high throughput screening for cancer-fighting immune cells and creates a massive new dataset that is perfectly suited for AI. We are excited to work with them as they build out their team and capabilities.” Modulus is first focused on developing therapies based on natural killer (NK) cells for the treatment of metastatic breast cancer, building on recent momentum in deploying these cells against solid tumors. Despite the rapid growth of the cell therapy market, the design of these cells is still largely a bespoke, craftsman-like process limited by human understanding of biology. “High throughput discovery approaches in cell types such as natural killer cells have lagged behind those in other cell types,” said Alana Welm, Scientific Advisor. “We’re really excited about the therapeutic prospects of exploring the different ways that these cells can be engineered.” Modulus was founded in 2020 by bioengineer Max Darnell, Ph.D. and bioinformatician Bryce Daines, Ph.D., who met as Entrepreneurs-in-Residence at AI2, a research institute created by Microsoft co-founder Paul Allen. The founders set out to invent a platform for systematic and repeatable discovery of next-generation cell therapies to unleash the potential of the immune system against solid tumors. “The AI2 Incubator's mission is to help founders launch AI companies that have the potential to change the world,” said Bryan Hale, Managing Director at the AI2 Incubator. "By harnessing cutting edge AI to seek out life-saving treatments for solid tumors, Modulus has the potential for a truly big impact." While much of the Cell Therapy industry remains focused on problems such as taking existing therapeutic cells and turning them against new targets, Modulus takes a broader approach. Rather than focusing on a single feature, such as targeting, Convergent Design™ enables simultaneous improvement along multiple axes of therapeutic importance converging on optimized cell designs. “Modulus is the only company we’ve seen which is focused on engineering the chassis of these cells.” said Rima Chakrabarti, MD, Principal at KdT Ventures. “By modulating the innate cellular machinery, Modulus can optimize not only for therapeutic efficacy but for improved manufacturability and storage as well, bringing us closer to curative, off-the-shelf immune cell therapies.” Modulus has reengineered the concept of Cell Therapy Discovery by dramatically increasing the number of candidate cells that can be tested simultaneously and using machine learning to interpret the results. As a result, Modulus can learn how entire networks of genes impact a cell’s function, not just one gene at a time. “By combining high-throughput screening with machine learning, to interpret and predict genetic interactions, we get a multiplier on our experimental throughput that dwarfs previous approaches,” said Bryce Daines, Ph.D., co-founder of Modulus. “Repeated over cell types and diseases the result is a flywheel of discovery.” “When combined, these technologies provide a path for discovering the enhancements that cells need to accomplish a complex therapeutic task, like fighting a solid tumor,” said Max Darnell, Ph.D., co-founder of Modulus. “Current cell therapy design is like trying to find your way out of the woods without a GPS. This platform gives us the tools to navigate the cell’s design space systematically and effectively.” For more information about Modulus, please visit https://www.modulustherapeutics.com/ or follow them on Twitter, LinkedIn, Facebook and Instagram. Alana Welm is Senior Director of Basic Science at the Huntsman Comprehensive Cancer Center, Full Professor in the Department of Oncological Sciences at the University of Utah, and an Investigator at the Huntsman Cancer Institute. Welm's laboratory studies breast cancer metastasis. Dr. Raphael Gottardo is Scientific Director, Translational Data Science Integrated Research Center, Professor, and J. Orin Eson Foundation Endowed Chair at Fred Hutch. Dr. Gottardo is a computational biologist and expert in the rapidly evolving field of data science as it is applied to cancer and related diseases. Modulus is engineering next-generation immune cell therapies, starting with Natural Killer cells rationally designed for the treatment of solid tumors. Modulus’ Convergent Design™ platform combines genetic engineering, machine learning, and high-throughput in vivo screening to systematically converge on optimized cell designs. Modulus is committed to the discovery of cell therapies to treat a broad set of patient populations not currently served by existing treatments and will use its platform to enable partners and develop an internal pipeline of therapeutics. Contact Details Owen Media Forrest Carman +1 206-859-3118 forrestc@owenmedia.com Company Website https://www.modulustherapeutics.com/

July 15, 2021 09:00 AM Pacific Daylight Time

Cyvatar Wins Grand Trophy in the Annual Disruptor Awards

Cyvatar

Cyvatar won its second Grand Trophy of the year during the 2021 Disruptor Company Awards. In addition to its Grand Trophy win, the company walked away with a gold award for security services and bronze for security cloud and SaaS. The disruptor awards judges recognize disruptors as highly persistent, mostly beginning from scratch without the constraints of traditionally accepted processes or business models. Instead, they use modern technology and tools to achieve superior end results. The excellence and innovation found in Cyvatar’s cybersecurity-as-a-service (CSaaS) offering has been recognized again and again since its debut last fall. The disruptor awards mark Cyvatar’s 17th win in eight months. “Like other disruptors, we do things differently at Cyvatar,” said Cyvatar Co-Founder and Chief Product and Strategy Officer Craig Goodwin. “We’re not hindered by legacy systems or bound by outdated solutions. We confidently face the challenges of providing security solutions that are effortless for our members to use and affordable for them to purchase.” Cyvatar brings the membership economy to cybersecurity with its innovative CSaaS model and a platform that has already become the de facto operating system for today’s security programs. It transforms cybersecurity for its customers and continually meets their ever-evolving business and security requirements. The company was selected from organizations around the world that vied for top honors. Its disruptive, game-changing platform delivers fast, affordable, fully managed security programs for any size business; processes designed to provide outcomes, continuous remediation, and ongoing solution maintenance; and the ability for all of its members to execute their security strategies at speed and scale. Does your organization need award-winning cybersecurity? Find out how Cyvatar can help. About Cyvatar Cyvatar is committed to effortless cybersecurity for everyone. As the industry’s first subscription-based, cybersecurity-as-a-service (CSaaS) company, it’s our mission to transform the way the security industry builds, sells, and supports cyber solutions. We empower our members to achieve successful outcomes by providing expert advisors, proven technologies, and a strategic process roadmap to guarantee results that map to their business drivers. Our approach is rooted in proprietary ICARM (installation, configuration, assessment, remediation, maintenance) methodology that delivers smarter, measurable security solutions for superior compliance and cyber-attack protection faster and more efficiently, all at a fixed monthly price. And because we’re a subscription, members can cancel anytime. Cyvatar is a global organization with operations around the world. Begin your journey to security confidence at https://cyvatar.ai/ and follow us on LinkedIn and Twitter. Contact Details Cyvatar KC Higgins +1 303-434-8163 kc@cyvatar.ai Company Website https://cyvatar.ai/

July 13, 2021 11:00 AM Eastern Daylight Time

Cortland Biomedical Announces Continued Growth

Cortland Biomedical

Cortland Biomedical, a full-service medical textiles product development partner that provides access to a full-spectrum of global engineering, design and manufacturing capabilities, today announced the appointment of three new hires. This comes on the heels of three hires being announced in April, and the completion of Cortland’s transition to a state-of-the art new facility. Wesley Conger has been appointed Director, Engineering and Product Development. Previously with Cortland’s industrial group, Wesley has a successful track record building and overseeing an engineering organization able to effectively manage complex projects and support customer needs. At Cortland Biomedical, he will provide leadership and direction to the medical engineering department and will be accountable for the performance and results of the team. He will also help to develop and apply engineering standards and procedures while ensuring medical products are engineered to meet or exceed customer expectations, internal design and stringent quality criteria. Wes holds a Bachelor of Science in mechanical engineering from Tulane University in Louisiana. Julia Wright has joined the company as a process engineer on the New Product Development team. She brings expertise in knitting and weaving and will develop and qualify processes supporting Cortland Biomedical’s product development funnel. She holds a Bachelor of Fine Arts in textiles from the Rhode Island School of Design. Mark Gruszkiewicz has joined as a senior technical specialist to work closely with the operations team on new product launches, and with the New Product Development team to develop new textile designs. He brings over 30 years of weaving experience and has held positions of increasing responsibility during his career as a material handler, weaver, knotter, loom technician and lead technician supervisor. He also has taken many technical trainings in weaving and weaving technology. “It’s an exciting time for Cortland Biomedical and we’re pleased to continue to grow our team with top-notch talent that shares our passion for overcoming the status quo in medical textile development,” said Eric Brown, Director of Operations, Cortland Biomedical. “Wesley has already demonstrated exceptional engineering skills within the Cortland organization, and will now be a great asset on the biomedical side. We also look forward to Julia and Mark’s contributions to new product development, operations and product launches.” The company is continuing to seek the brightest engineering and technical talent from across the industry. See available positions here. About Cortland Biomedical Cortland Biomedical custom designs and manufactures high-performance biomedical textile structures leveraging years of experience in medical textile engineering methods including knitting, braiding and weaving. Its thoughtful design concepts challenge the status quo. Cortland Biomedical’s unique combination of advanced equipment and technology, a seasoned medical textile-specific engineering team, and first-rate R&D capabilities allows it to tackle customers’ complex challenges with the innovation and agility expected in the medical device industry. Learn more at cortlandbiomedical.com. Contact Details Jordan Bouclin, SVM Public Relations +1 401-490-9700 Jordan.bouclin@svmpr.com

July 13, 2021 10:05 AM Eastern Daylight Time

NextFerm Technologies obtains Regulatory Approval to market Astaferm® Astaxanthin Antioxidant in Canada

NextFerm Technologies Ltd.

NextFerm Technologies (TASE:NXFR), a food-tech company developing ProteVin™, a vegan, yeast-based, non-GMO protein alternative and other innovative yeast-based nutrients, today announced that Health Canada has granted a regulatory marketing approval for Astaferm®, its innovative fermented astaxanthin antioxidant in the form of Gummies. This is the only fermented astaxanthin with no odor and flavor. Along with the receipt of Astaferm®’s license approval (NPN - Natural Product Number), the company is preparing for the launch of several applications of Astaferm® in North America, including for Immunity support, which is a growing segment due to the Covid-19 pandemic. The Company has already supplied initial quantities of Astaferm® in Canada and is currently in dialogues with potential customers. Astaferm® has a US Self GRAS regulatory approval and was launched in the US at the end of 2020. The product is in early stages of sales, by well-known US dietary supplement brands, such as Carlson Labs and Purity Products. Since Astaferm® is flavorless and odorless, the Gummies application constitutes a significant differentiation from other astaxanthin products available on the market, produced from algae with fishy odor, and therefore applied mainly in soft-gels. NextFerm currently prepares to expand the marketing of Astaferm® for additional indications such as immune system support, as well as expanding into additional serving forms, such as water-dispersible powder for food and beverages, and fermented Astaferm® oil for soft-gels with competitive pricing. Boaz Noy, Chief Executive Officer of NextFerm, said, “The regulatory approval received for Astaferm® in Canada strengthens our presence in the North American dietary supplement market. This emphasizes Nextferm's ability to bring innovative nutritional ingredients from R&D to commercialization and sales. We have already started with an initial supply of the product to a customer in Canada and anticipate further launches in light of the differentiation with competing algae-based products that have fishy odor. This is thanks to a unique value proposition that combines a high astaxanthin concentration, without flavor and odor, which allows it to be integrated in delicious gummies and other food applications. At the same time, we are progressing according to our plan for the commercial launch of ProteVin ™, our vegan protein, in 2022.” About NextFerm Technologies NextFerm Technologies, traded on the Tel Aviv Stock Exchange (TASE:NXFR) is a food-tech company engaged in the research, development, manufacturing and marketing of innovative, functional and vegan yeast-derived, non-GMO protein alternatives for various applications in the food and food supplement markets and the growing market for animal-derived protein alternatives. NextFerm's flagship product is ProteVin™, a vegan, yeast-derived protein alternative with nutritional value that is similar to animal-derived protein and a neutral flavor, with no aftertastes that are typical of plant-based protein. ProteVin™ is designed for a variety of categories in the alternative protein market, which is estimated at $13 billion, with an annual growth rate of 10%, including milk and dairy substitutes, meat substitutes and additional categories such as infant nutrition, adult nutrition, and sports nutrition. NextFerm is gearing up for commercialization of the product in the US in 2022. Another product currently being sold is Astaferm®, an innovative astaxanthin-based antioxidant derived from yeast that has been sold in the US since the end of 2020 through well-established and leading brands in the food supplement market in the US. The company has additional products which have been licensed to Lallemand, a global giant focused on yeast. For more information, visit the NextFerm website at: www.nextferm.com Legal Notice Regarding Forward-Looking Statements This announcement also includes forecasts, projections, assessments, estimates and other information which refer to future events and matters, the realization of which is uncertain and not exclusively under the Company’s control (forward-looking information). The main facts and data used to support this information are facts and data regarding the current position of the Company and its businesses (including the scope of sales and levels of profitability, manpower, commercial engagements and more), facts and data regarding the current global position of the Company’s operating segments (including industry-specific financial developments, environmental regulatory developments, the competitive environment, technological developments, the reinsurance market and more), and macro-economic facts and data (including the economic situation both in Israel and around the world, yields in the capital markets, social and state developments and more), all as known by the Company when publishing this announcement. The forward-looking information included above in this announcement is significantly based upon, in addition to the existing information held by the Company, on the Company’s current assessments and expectations of future developments vis-a-vis each one of the aforementioned parameters, and the interconnectedness of each one of these developments. The Company has no certainty that its forecasts and assessments will indeed eventuate, and the Company’s operating results may be materially different than the results assessed or implicit based on that set forth above, inter alia, as a result of a change in any of the aforementioned factors. Contact Details NextFerm Technologies Ltd. Yossi Ohana - Chief Financial Officer +972 54-771-5893 yossio@nextferm.com Investor and Media Contact Meirav Gomeh-Bauer +972544764979 meirav@bauerg.com Company Website https://www.nextferm.com/

July 12, 2021 12:51 PM Eastern Daylight Time

New Website Created by Quidel Corporation Provides Consumers With Information and Easy-to-Understand Answers Regarding Lyme Disease

Quidel Corporation

Americans looking for information regarding Lyme disease, often referred to as the “epidemic within the pandemic,” now have a new and trusted resource in which to rely with the launch of LymeDiseaseAnswers.com. Created by Quidel Corporation, the website provides consumers with the peace of mind that comes with increased knowledge of the prevalence, causes, warning signs, symptoms and advances in the testing of Lyme disease, which afflicts nearly 480,000 people across the country each year. “Lyme disease can strike anyone of any age, especially those who spend time in wooded or grassy areas or who play sports on grass fields in high-risk areas of the country,” said Cheryl Miller, vice president of new market development for Quidel. “People are rightfully concerned about contracting Lyme disease and want to know how to avoid it, especially now with Americans spending more and more time outdoors as we emerge from the COVID-19 pandemic. We’ve created LymeDiseaseAnswers.com as a consumer-friendly and straight-talk place where people can easily find the information they are seeking.” The new website, created in tandem is Quidel’s strategic and creative partner breakwhitelight, contains answers to frequently asked questions, easy-to-understand infographics showing where Lyme disease is most prevalent and how it is contracted, the latest statistics and clinical research taking place regarding the disease, and links to additional resources on the subject. Also housed on the site is a series of recently produced “Quick Takes”—attention-grabbing educational videos that help consumers and health care professionals alike enhance their knowledge of Lyme disease by providing the information and up-to-the-minute data needed to confront this disease quickly and clearly. Quidel is the diagnostic health care manufacturer behind the industry’s most rapid and reliable in-office test for Lyme disease, the Sofia 2 Lyme FIA test. This test provides a patient as well as his or her physician with indicative results within minutes as opposed to days, which has historically been the norm. Performed in the privacy of a doctor’s office or local clinic, it is also the only test that can get results from a simple finger prick of blood. Given that the vast majority of patients tested are negative, not having to wait days for test results allows physicians and nurse practitioners to more rapidly treat those patients with positive results while more quickly pursuing other diagnosis and treatment for those who test negative. While just launching this month, LymeDiseaseAnswers.com has already been honored for excellence by the renowned MarCom Awards, an international creative competition that recognizes outstanding achievement by marketing and communications professionals, both corporate and agency. LymeDiseaseAnswers.com received MarCom’s highest award—its Platinum Award—while competing against more than 6,500 entries from the United States and several foreign countries. About Quidel Corporation Quidel Corporation (Nasdaq: QDEL) is a leading manufacturer of diagnostic solutions at the point of care delivering a continuum of rapid testing technologies that further improve the quality of health care throughout the globe. An innovator for over 40 years in the medical device industry, Quidel pioneered the first FDA-cleared point-of-care test for influenza in 1999 and was the first to market a rapid SARS-CoV-2 antigen test in the U.S. Under trusted brand names Sofia®, Solana®, Lyra®, Triage® and QuickVue®, Quidel’s comprehensive product portfolio includes tests for a wide range of infectious diseases, cardiac and autoimmune biomarkers, as well as a host of products to detect COVID-19. With products made in America, Quidel’s mission is to provide patients with immediate and frequent access to highly accurate, affordable testing for the good of our families, our communities and the world. For more information about Quidel, visit quidel.com. Contact Details Jim Yeager +1 818-264-6812 jim@breakwhitelight.com Company Website http://Quidel.com

July 12, 2021 09:00 AM Eastern Daylight Time

Image

Cyvatar Takes Home Top Prize in 2021 Fortress Awards

Cyvatar

Cyvatar today received more industry accolades as it was named a winner in network security by the Business Intelligence Group for its innovative Cybersecurity-as-a-Service (CSaaS) offering as part of the 2021 Fortress Cybersecurity Awards. The Fortress awards program identifies and rewards the world’s leading companies and products that are working to keep data and electronic assets safe among a growing threat from hackers. “2021 is rapidly becoming the toughest year for cybersecurity professionals and as our reliance on networks continues to accelerate, our identities and data have quickly become global currency, so security is more important than ever,” said Maria Jimenez, chief nominations officer at the Business Intelligence Group. “We are proud to recognize all of our winners and finalists who are on the frontlines of the effort to prepare, defend and respond to this growing threat.” Cyvatar’s proprietary ICARM method guarantees proper installation, configuration, assessment, remediation, and maintenance for every Cyvatar technology solution so that organizations actually achieve better protection and resilience from their investments And because Cyvatar’s method is continuous, it protects against attack vectors that haven’t even surfaced yet. “It’s continued validation of our unique CSaaS model that industry peers recognized Cyvatar again for exceptional leadership and innovation,” said Cyvatar Co-Founder and Chief Product and Strategy Officer Craig Goodwin. “As the first subscription-based CSaaS company to deliver effortless, affordable cybersecurity, we enable our members to protect confidential information with the people, processes, and technology essential to ensure they get value from their security tools, from conception and strategy to implementation and maintenance. No other provider delivers holistic security at price points that work for any size customer and guaranteed value that allows customers to cancel anytime.” Cyvatar CSaaS levels the playing field by democratizing cybersecurity and making the best protection accessible and affordable for every size organization, even if they have no cybersecurity expertise in-house. If your organization needs award-winning cybersecurity, Cyvatar can help. About Cyber Defense Magazine With over 5 Million monthly readers and growing, and thousands of pages of searchable online infosec content, Cyber Defense Magazine is the premier source of IT Security information for B2B and B2G with our sister magazine Cyber Security Magazine for B2C. We are managed and published by and for ethical, honest, passionate information security professionals. Our mission is to share cutting-edge knowledge, real-world stories and awards on the best ideas, products and services in the information technology industry. We deliver electronic magazines every month online for free, and special editions exclusively for the RSA Conferences. CDM is a proud member of the Cyber Defense Media Group. Learn more about us at https://www.cyberdefensemagazine.com and visit https://www.cyberdefensetv.com and https://www.cyberdefenseradio.com to see and hear some of the most informative interviews of many of these winning company executives. Join a webinar at https://www.cyberdefensewebinars.com and realize that infosec knowledge is power. About Cyvatar Cyvatar is committed to effortless cybersecurity for everyone. As the industry’s first subscription-based, cybersecurity-as-a-service (CSaaS) company, it’s our mission to transform the way the security industry builds, sells, and supports cyber solutions. We empower our members to achieve successful outcomes by providing expert advisors, proven technologies, and a strategic process roadmap to guarantee results that map to their business drivers. Our approach is rooted in proprietary ICARM (installation, configuration, assessment, remediation, maintenance) methodology that delivers smarter, measurable security solutions for superior compliance and cyber-attack protection faster and more efficiently, all at a fixed monthly price. And because we’re a subscription, members can cancel anytime. Cyvatar is headquartered in Irvine, California with locations around the world. Begin your journey to security confidence at CYVATAR.AI and follow us on LinkedIn and Twitter. Contact Details Cyvatar KC Higgins +1 303-434-8163 kc@cyvatar.ai Cyber Defense Magazine April Palanca +18338449468 Company Website https://cyvatar.ai/

July 07, 2021 11:51 AM Eastern Daylight Time

Introducing YuCALM®, Natural Calming Chews for Stressed or Anxious Dogs

Lintbells

Lintbells, manufacturer of leading hip and joint supplement for dogs, YuMOVE®, is excited to announce its latest in natural* health products with the launch of YuCALM®. Available on Chewy.com, YuCALM® ONE-A-DAY chews for dogs of all sizes, contains science-backed ingredients to help dogs cope with stress and anxiety. “Many dogs feel anxious on a daily basis or are fearful toward specific triggers such as thunderstorms, fireworks, or new situations like owners returning back to the office,” said John Howie, CEO and co-founder of Lintbells. “By supporting natural calming pathways in the brain, YuCALM® ONE-A-DAY is a safe and effective way to reduce stress and support calm behavior.” Easy to use format. YuCALM® ONE-A-DAY comes in a handy tasty bite dogs love, that makes feeding a breeze. Lemon balm helps dogs feel more relaxed, soothing stress and encouraging calming behavior. L-Theanine offers natural calming properties that support the production of calming compounds such as serotonin. B Vitamins support healthy brain function, reducing excitability and improving concentration. Proprietary blend of natural fish protein hydrolysates helps calming signals locate the right spot in the brain. “We recommend pets be on a daily regimen of YuCALM® approximately four to six weeks in advance of any expected triggering events such as holiday celebrations, major traveling, or family members heading back to school,” adds Howie. “We’re thrilled to offer pet owners a safe and effective solution for their anxious four-legged friends.” Product samples, images, and veterinary and expert interviews available upon request. *Over 90% of ingredients natural. For the full definition please visit yumove.com/natural. About Lintbells Lintbells, the UK's #1 Vet Recommended Dog Joint Supplement company, currently helps more than 1 million dogs across Europe and the United States. In March 2019, Lintbells officially entered the US Market with the introduction of their most popular product abroad, YuMOVE Soft Chews. This joint supplement promotes joint and cartilage health in dogs of all breeds and sizes. Made from all-natural, human-grade, non-GMO ingredients, the secret to YuMOVE Soft Chews' success comes from Lintbells own ActivEaseÂ® Green Lipped Mussel (or GLM). GLM, a superfood derived from the purest sources in New Zealand, is an essential ingredient with extraordinary properties that improves joint function, mobility, and reduces discomfort in our dogs. This unique ingredient, rich with more Omega 3s than any other GLM, is naturally anti-inflammatory, meaning our dog's stiff joints are eased naturally. To learn more, visit www.yumove.com Contact Details The Impetus Agency Jamie Baxter +1 775-322-4022 jamie@theimpetusagency.com Company Website https://yumove.com/

July 07, 2021 06:12 AM Pacific Daylight Time

GROUNDWORK BIOAG EXPANDS LEADERSHIP TEAM FOR GLOBAL GROWTH OF MYCORRHIZAL PLATFORM

Groundwork BioAg

• Former ICL Fertilizers and Chemicals CEO Hanan Dor Joins to Lead Agriculture Business • Co-Founder Dan Grotsky to Lead Expansion of Cannabis and Growth Initiatives Groundwork BioAg ® announced today that the company has expanded its leadership team to directly align with its key growth markets: mainstream agriculture and cannabis, in response to increased demand for its regenerative agriculture products. Former Chief Executive Officer of ICL Fertilizers and Chemicals, a subsidiary of ICL Group LTD, Hanan Dor has joined the company as Chief Commercial Officer, responsible for expanding the agriculture business. He brings more than 35 years of experience leading global business development, marketing and sales for sustainable specialty fertilizer plant nutrition. During his time in leadership roles, ICL tripled its global business and expanded in key commodity agriculture markets, including China and India. Co-Founder Dan Grotsky is named Chief Growth Officer, responsible for expanding the cannabis business and growth initiatives, including sustainability and carbon markets. Since Groundwork BioAg’s inception in 2014, Grotsky led the development of globally recognizable brands, Rootella ® for row, organic and specialty crops, and DYNOMYCO ® for cannabis. His shift in responsibility reflects the company’s goal to build upon this foundation and accelerate its market leadership position in bioagriculture. “We’re thrilled to attract an industry leader like Hanan to our leadership team. Together, I believe Groundwork BioAg is well positioned to continue our rapid growth trajectory,” said Dr. Yossi Kofman, Co-Founder and CEO of Groundwork BioAg. “Along with insights from the specialty fertilizer industry, Hanan shares our passion for mycorrhiza – the queen of biologicals – and understands its central role to building a bio-platform accessible to farmers around the world. Coupled with Dan’s vision for these brands and the dedication of our entire team, I am confident we will deliver upon our goals.” Groundwork BioAg’s mainstream ag business delivered record sales in both the 2019 and 2020 growing seasons and doubled its cannabis business. In May, the company secured new funding to accelerate mass production of its highly concentrated, cost-effective mycorrhizal inoculants and expand its technology platform to support ongoing innovation. In addition to increasing yield, mycorrhizae improve sustainability by reducing dependency on phosphorus fertilizer and improving carbon sequestration in soil. Through distribution partnerships across five continents, Groundwork BioAg is helping farmers improve the efficiency and profitability of major crop production, including corn, soybeans, grains, bio-energy crops, vegetables and cannabis. About Groundwork BioAg Groundwork BioAg, a global bioagriculture company, leverages the natural power of mycorrhizal fungi to improve the productivity, sustainability and profitability of commercial agriculture and expand regenerative agriculture practices. Groundwork BioAg is the first to use innovative techniques to solve challenges inherent in high-volume mycorrhizal inoculant production. We will not rest until every hectare of arable land is protected by mycorrhizae and every farmer benefits from higher crop yields while preserving our soils. For more information, visit www.groundworkbioag.com. Contact Details AgTech PR Jennifer Goldston +1 816-260-0040 jennifer@agtechpr.com Company Website https://www.groundworkbioag.com

July 07, 2021 07:00 AM Eastern Daylight Time

Image

1 ... 156 157 158 159 160 ... 187